Netum provided preliminary H1/2022 figures, with growth better than we had expected while profitabil...
Redeye leaves its view on Xspray following friday's Q2 report, where it announced a vision of genera...
ChemoTech är ett svenskt medicinteknikföretag med säte i Lund, som utvecklat ett nytt behandlingsalt...
Safe at Sea tillverkar sök- och livräddningsbåtar för SAR-verksamhet (Search and Rescue).
Redeye lowers its full-year sales estimates for 2022E from SEK 180m to SEK 149m and our 2023-2024E s...
We raise our full-year group clean EBIT forecast by ~50%.
Redeye updates our outlook on XVIVO. The company had underperformed the local equity market despite ...
Redeye considers BIMobject’s figures to be overall in line with our expectations, but mainly driven ...
Net sales was in line with consensus (Refinitiv) in Q2.
Redeye is positive about the work done by Moberg Pharma to further strengthen their partner network ...
Enersense’s Q2 was weak, and H2 is set to remain modest.
Scanfil’s Q2 report didn’t serve any major surprises.
We expect DKK 80m in H1 2022 Sales Significant market potential if SPENN is successful Uncertainty...
Profit before tax at DKK 54m, 8% above ABGSCe Growth in Greenland on track Strong quarter on insur...
CapMan reported Q2 EBIT of EUR 14.1m, 11% above Refinitiv consensus.
Following BankNordik's Q2 2022 report, we lift 2022E-24E adjusted EPS by ~1%, primarily due to impro...
Omsättningen sjönk under kvartalet på grund av minskad covid-relaterad försäljning.
Enersense’s Q2 results were known before the official release as the company disclosed preliminary f...
Redeye is positive about the news that the FDA has approved ISAB’s proposal for a research study aim...
Redeye is disappointed by Isofol’s phase III AGENT trial failing to meet its primary ORR and key sec...
